Institutional vial orders rose 31% sequentially to 926; July orders climbed to 383, the largest month to date.
Leonard Mazur said a 29-person commercial team now provides nationwide coverage, targeting formulary inclusion at 100 priority institutions by year-end.
Fiscal Q3 results and cash position
Citius Oncology posted revenue of $1.49 million for fiscal Q3 ended June 30, 2026, versus no revenue a year earlier.
Net loss widened to $8.92 million, or $0.08 per share, from $5.37 million, or $0.08 per share.
Cash and cash equivalents rose to $16.56 million as of June 30, 2026; nine-month revenue reached $7.11 million.
CTOR•
